MedTrace Logo

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

NCT05326347 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2024-10-30

No results posted yet for this study

Summary

Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia

Conditions

Interventions

DRUG

OPC-34712FUM/ Brexpiprazole fumarate

The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Takeshi Tsunoda · Otsuka Pharmaceutical Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2025-08-31
Completion
2025-09-30

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326347 on ClinicalTrials.gov